Aurealis Therapeutics shared the results of its DIAMEND Phase 2 clinical trial of AUP-16 for non-healing Diabetic Foot Ulcers (DFUs) at the European Wound Management Association (EWMA) 2026 Conference, taking place from 6–8 May in Bremen, Germany. The results were presented by Professor Alberto Piaggesi, Global Coordinating Investigator of the study on Thursday 7 May, 2026.
In addition, Aurealis’ CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake attended the conference to share insights into the next stage of AUP-16’s development, including preparations for the upcoming Phase 3 clinical trial, as well as to engage with partners across the wound care ecosystem.
As Europe’s leading conference in wound management, EWMA brings together clinicians, researchers, and industry leaders to present the latest developments, exchange knowledge and advance standards of care. Aurealis’ participation in EWMA 2026 reflects its commitment to staying up to date with scientific and clinical developments while actively contributing to progress in the field.
Following the completion of its Phase 2 clinical trial, Aurealis continues to advance AUP-16 toward the next stage of development. As we move into Phase 3, continued collaboration across the wound care community will play an important role.